Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

When scientists first came across p53 in 1979, it was an intriguing but not Earth-shattering discovery. Six groups independently discovered a cellular protein with a molecular weight of roughly 53 ...

The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

You have recently been appointed as the new Scientific Director of the Ludwig Institute for Cancer Research. Can you share with us why you decided to join Ludwig? I’m really delighted to join the ...

(“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the ...

RECIST 1.1 versus immune-related RECIST and immune-related response criteria in assessing response to nivolumab in patients with lung, renal, and head and neck cancers. Measurement of PD-1, TIM-3 and ...

CAMBRIDGE, MA. & ROCKVILLE, MD.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation TCEs, today announced new data ...

An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced ...

Previous studies have suggested that resveratrol — the chemical compound found in grapes and red wine — may have anticancer properties. But now, a new study shows how the compound can stop a mutated ...